[go: up one dir, main page]

MX2007003267A - Memantina para el tratamiento de trastornos de conducta en la infancia. - Google Patents

Memantina para el tratamiento de trastornos de conducta en la infancia.

Info

Publication number
MX2007003267A
MX2007003267A MX2007003267A MX2007003267A MX2007003267A MX 2007003267 A MX2007003267 A MX 2007003267A MX 2007003267 A MX2007003267 A MX 2007003267A MX 2007003267 A MX2007003267 A MX 2007003267A MX 2007003267 A MX2007003267 A MX 2007003267A
Authority
MX
Mexico
Prior art keywords
memantine
treatment
behavioral disorders
childhood behavioral
childhood
Prior art date
Application number
MX2007003267A
Other languages
English (en)
Inventor
Sandeep Gupta
Hans-Joerg Moebius
Jeffrey Jonas
Pradeep K Banerjee
Allison Mann
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35445934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007003267(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of MX2007003267A publication Critical patent/MX2007003267A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Un metodo para el tratamiento de individuos con diagnostico de trastorno de conducta infantil, tal como los trastornos del espectro autista o la forma combinada del Trastorno de deficit de atencion con Hiperactividad (ADHD) mediante la administracion de una cantidad eficaz de memantina.
MX2007003267A 2004-09-23 2005-09-23 Memantina para el tratamiento de trastornos de conducta en la infancia. MX2007003267A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61260004P 2004-09-23 2004-09-23
PCT/US2005/034199 WO2006034465A1 (en) 2004-09-23 2005-09-23 Memantine for the treatment of childhood behavioral disorders

Publications (1)

Publication Number Publication Date
MX2007003267A true MX2007003267A (es) 2007-05-23

Family

ID=35445934

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003267A MX2007003267A (es) 2004-09-23 2005-09-23 Memantina para el tratamiento de trastornos de conducta en la infancia.

Country Status (16)

Country Link
US (2) US20060079582A1 (es)
EP (1) EP1799224A1 (es)
JP (1) JP2008514620A (es)
KR (1) KR20070046185A (es)
CN (1) CN101374525A (es)
AR (1) AR052643A1 (es)
AU (1) AU2005286672B2 (es)
BR (1) BRPI0515560A (es)
CA (1) CA2578953A1 (es)
EA (1) EA012036B1 (es)
IL (1) IL182105A0 (es)
MX (1) MX2007003267A (es)
NO (1) NO20072035L (es)
TW (1) TW200626160A (es)
WO (1) WO2006034465A1 (es)
ZA (1) ZA200702130B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456224B2 (en) 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine
RU2326660C1 (ru) * 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты)
US20100292341A1 (en) * 2007-06-29 2010-11-18 Orchid Chemicals & Pharmaceuticals Limited Quick dissolve compositions of memantine hydrochloride
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
EP2138173A1 (en) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmaceutical compositions comprising aminoadamantane derivatives
PL2201950T3 (pl) * 2008-12-08 2017-06-30 Biocodex Związki i sposoby leczenia zaburzeń ze spektrum autyzmu
IT1396556B1 (it) * 2009-02-11 2012-12-14 Serra Uso di memantina per il trattamento di disturbi dell umore
MX346185B (es) 2010-11-15 2017-03-10 Agenebio Inc Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo.
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
WO2014015047A1 (en) 2012-07-17 2014-01-23 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
KR101424514B1 (ko) * 2013-01-02 2014-07-31 건국대학교 산학협력단 선천성 발프로산 노출 증후군 치료제로서의 메만틴의 용도
EP3485882A1 (en) 2013-01-25 2019-05-22 Case Western Reserve University Compositions for the treatment of pervasive development disorders
WO2014153180A1 (en) * 2013-03-14 2014-09-25 Michela Gallagher Methods and compositions for improving cognitive function
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN114470009A (zh) * 2015-05-22 2022-05-13 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
EP3310785B1 (en) 2015-06-19 2024-11-20 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
RU2746000C2 (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3661492B1 (en) * 2017-08-01 2024-12-25 Stuart A. Lipton Nitrosynapsin for use in treating autism spectrum disorder
US20190091179A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
ES2997869T3 (en) 2017-11-22 2025-02-18 Panorama Res Inc Aminoadamantyl nitrate compounds and their use to treat cns disorders
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
CA3104478A1 (en) 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US12144787B2 (en) 2018-11-19 2024-11-19 Zogenix International Limited Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5)
US20240130675A1 (en) * 2021-02-03 2024-04-25 The General Hospital Corporation Methods for Treating Autism Spectrum Disorder
AU2024211402A1 (en) * 2023-01-27 2025-08-21 Hyloris Developments Sa Use of vitamin e tpgs as a taste masking agent for bitter drugs

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7305644A (es) * 1972-04-20 1973-10-23
HU169986B (es) * 1972-12-07 1977-03-28
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4849222A (en) * 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
DE10299048I2 (de) * 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US6326226B1 (en) * 1997-07-15 2001-12-04 Lg. Philips Lcd Co., Ltd. Method of crystallizing an amorphous film
CN1293573A (zh) * 1998-01-13 2001-05-02 同步神经元有限责任公司 迟发性运动障碍和其它运动疾病的治疗方法
AU4517201A (en) * 1999-12-08 2001-06-18 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
US6727231B1 (en) * 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
WO2003061656A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
US20040019118A1 (en) * 2002-07-19 2004-01-29 Khalid Iqbal NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease

Also Published As

Publication number Publication date
JP2008514620A (ja) 2008-05-08
NO20072035L (no) 2007-06-13
AU2005286672A1 (en) 2006-03-30
EA012036B1 (ru) 2009-06-30
IL182105A0 (en) 2007-07-24
WO2006034465A8 (en) 2006-06-08
TW200626160A (en) 2006-08-01
AU2005286672B2 (en) 2009-03-12
CN101374525A (zh) 2009-02-25
EP1799224A1 (en) 2007-06-27
CA2578953A1 (en) 2006-03-30
US20060079582A1 (en) 2006-04-13
US20100081723A1 (en) 2010-04-01
EA200700708A1 (ru) 2007-08-31
WO2006034465A1 (en) 2006-03-30
AR052643A1 (es) 2007-03-28
BRPI0515560A (pt) 2008-07-29
ZA200702130B (en) 2008-09-25
KR20070046185A (ko) 2007-05-02

Similar Documents

Publication Publication Date Title
MX2007003267A (es) Memantina para el tratamiento de trastornos de conducta en la infancia.
TW200626989A (en) Multifocal lenses for pre-presbyopic individuals
TW200714283A (en) Method and composition for treating peripheral vascular diseases
TW200510301A (en) Novel compounds
TW200510303A (en) Novel compounds
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
IL176674A0 (en) Fc region variants
TW200738270A (en) Method of treating depression using a TNFα antibody
MY177564A (en) Anti-nr10 antibody and use thereof
EA201100748A1 (ru) Пиразиновые соединения в качестве ингибиторов фосфодиэстеразы 10
CY1110931T1 (el) Μεθοδος αγωγης της ανωμαλης κυτταρικης αναπτυξεως
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
MX2007016469A (es) Metodos de tratamiento utilizando ansamicinas de hidroquinona.
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
IN2014DN05011A (es)
MX2007005936A (es) Una sintesis asimetrica del acido (s)-(+)-3-(aminometil)-5- metilhexanoico.
WO2007100777A3 (en) Methods for the treatment of adhd and related disorders
TW200642690A (en) Composition for treating central nervous system disorders
WO2008100727A3 (en) High-dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
MY154715A (en) Anti-nr10 antibody and use thereof
TW200637804A (en) Substantially pure tolterodine tartrate and process for preparing thereof
TW200510398A (en) Novel compounds
TW200604149A (en) Norbornane based cycloaliphatic compounds containing nitrile groups
WO2008034071A3 (en) Method of identifying patients suitable for high-dose cyclophosphamide treatment